KTTA’s PAS-004 advances Phase 1 for NF1 and MAPK-driven cancers
PAS-004 is advancing through Phase 1 trials for NF1 and MAPK-driven cancers, aiming to address major unmet needs with improved dosing and tolerability. Early data point to promising efficacy and safety, especially for NF1-CN.
PAS-004 is advancing through Phase 1 trials for NF1 and MAPK-driven cancers, with the programme focused on significant unmet needs and on improving dosing and tolerability. Early data point to promising efficacy and safety, and the company said the market opportunity is substantial, particularly for NF1-CN.